NYSEARCA:PBE Invesco Biotechnology & Genome ETF (PBE) Price, Holdings, & News $95.80 -0.52 (-0.54%) As of 10:08 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest About Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PBE alerts:Sign Up Key Stats Today's Range$95.37▼$96.2250-Day Range$84.74▼$98.7352-Week Range$67.69▼$98.82Volume1,701 shsAverage Volume12,963 shsMarket Capitalization$301.77 millionAssets Under Management$399.07 millionDividend Yield1.61%Net Expense Ratio0.58%Aggregate RatingModerate Buy ETF Overview PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser. Read More Invesco Biotechnology & Genome ETF ExpensesTypePBEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.50%0.55%0.57%0.51%0.53%Other Expenses0.08%0.52%0.53%0.60%0.54%Total Expense0.58%0.76%0.75%0.75%0.73%Fee Waiver0.00%-0.85%-0.67%-0.77%-0.68%Net Expense0.58%0.58%0.63%0.57%0.60% Receive PBE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invesco Biotechnology & Genome ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBE ETF News Headlines(PBE) Invesco Biotechnology & Genome ETFAugust 29 at 5:45 PM | sa.investing.comInvesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?August 19, 2026 | finance.yahoo.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.August 31 at 1:00 AM | Altimetry (Ad)XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?August 1, 2026 | fool.comVHT vs. PBE: Which Health Care ETF Is the Better Buy?July 30, 2026 | finance.yahoo.comETF Showdown: XBI vs PBE, Which Biotech Fund Wins?July 24, 2026 | 247wallst.comSee More Headlines PBE ETF - Frequently Asked Questions How have PBE shares performed this year? Invesco Biotechnology & Genome ETF's stock was trading at $82.15 on January 1st, 2026. Since then, PBE shares have increased by 17.2% and is now trading at $96.32. Who are Invesco Biotechnology & Genome ETF's major shareholders? Invesco Biotechnology & Genome ETF's top institutional shareholders include Dynamic Advisor Solutions LLC (0.17%), Compass Financial Management LLC (0.01%) and Compass Financial Management LLC (0.01%). How do I buy shares of Invesco Biotechnology & Genome ETF? Shares of PBE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Invesco Biotechnology & Genome ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invesco Biotechnology & Genome ETF investors own include Micron Technology (MU), Pfizer (PFE), Devon Energy (DVN), Intel (INTC), NVIDIA (NVDA) and Bristol Myers Squibb (BMY). Fund Details IssuerInvesco Fund NameInvesco Biotechnology & Genome ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:PBE Inception Date6/23/2005 Fund ManagerPeter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser Webwww.invescopowershares.com Phone+1-800-9830903Fund Focus Asset ClassEquity BenchmarkDynamic Biotech & Genome Intellidex Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings30 Fund Statistics Assets Under Management$399.07 million Average Daily Volume$51.19 thousand Discount/Premium-0.07% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorInvesco Capital Management, LLC CustodianThe Bank of New York Mellon Corporation DistributorInvesco Distributors, Inc. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCitadel Options OptionableN/A Short Interest17,905 shs Miscellaneous Outstanding Shares3,150,000Beta0.70 Creation Unit10,000 Creation Fee$500.00 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report Top 10 PBE HoldingsRegeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 5.44%Amgen (NASDAQ:AMGN)Holding Weight: 5.36%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 5.23%CareDx (NASDAQ:CDNA)Holding Weight: 5.19%Royalty Pharma (NASDAQ:RPRX)Holding Weight: 4.76%Biogen (NASDAQ:BIIB)Holding Weight: 4.69%Gilead Sciences (NASDAQ:GILD)Holding Weight: 4.40%United Therapeutics (NASDAQ:UTHR)Holding Weight: 3.83%Protagonist Therapeutics (NASDAQ:PTGX)Holding Weight: 3.59%Bio-Techne (NASDAQ:TECH)Holding Weight: 3.56%Full Holdings DetailsPBE Sector ExposurePBE Industry Exposure This page (NYSEARCA:PBE) was last updated on 8/31/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Biotechnology & Genome ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PBE Stock Alerts